Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Orexigen grants Valeant license to sell Contrave in Australia, New Zealand

Executive Summary

Orexigen Therapeutics Inc. licensed Valeant Pharmaceuticals International Inc. rights to commercialize its obesity therapy Contrave (naltrexone HCl/bupropion HCl extended release) in Australia and New Zealand.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies